Vertex Pharmaceuticals Incorporated (VRTX) Company Bio
Vertex Pharmaceuticals engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. The company was founded in 1989 and is based in Boston, Massachusetts.
VRTX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Vertex Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Vertex Pharmaceuticals Inc ranked in the 98th percentile in terms of potential gain offered. Our DCF analysis implies the stock could yield a return of 20484.17% if fairly valued; such returns are always unlikely, though, so further investigation is likely warranted. In terms of the factors that were most noteworthy in this DCF analysis for VRTX, they are:
The compound growth rate in the free cash flow of Vertex Pharmaceuticals Inc over the past 3.75 years is 2.59%; that's higher than 93.01% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than merely 5.06% of the free cash flow producing stocks we're observing.
VRTX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 54.9% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as VRTX, try KMDA, ASNB, GEN, AMEH, and AMRX.
BOSTON--(BUSINESS WIRE)-- #ECFS2020--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 43rd European Cystic Fibrosis Digital Conference (ECFS) held September 24-25, 2020 and the 2020 North American Cystic Fibrosis Virtual Conference (NACFC) taking place October 7-23, 2020. An oral presentation at the ECFS Digital Conference will highlight, for the first time, interim results from the TRIKAFTA
The greatest investment reward comes to those who by good luck or good sense find the occasional company that over the years can grow far more than the industry as a whole. - Phillip Fisher (Warren Buffett's mentor asides from Ben Graham) As you can see, biotech is a lucrative...
BioSci Capital Partners on Seeking Alpha | September 18, 2020
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DAL, SGMS, GME, VRTX, and FBIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has validated a Type II Variation Marketing Authorization Application (MAA) for the expanded indication of KAFTRIO®* (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat CF in patients ages 12 years and older with at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. If approved, eligible